The firm is hoping that the CRISPR/Cas9-edited TILs will have anti-tumor activity with long-term persistence against various solid tumors.

While skin cancer rates are growing in many parts of the world, experts disagree on whether this represents a true epidemic or overdiagnosis is a contributing factor.